1-6 of 6
Hamid Sayar, MD, MSc
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD PhD, Hamid Sayar, MD MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD, William Tse, MD FACP, Sang Kyun Sohn, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Hervé Dombret, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-137669
Published: 2020
Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Andrew H. Wei, MBBS, FRACP, FRCPA, PhD, Hartmut Döhner, MD, Christopher Pocock, MBBS, Pau Montesinos, MD PhD, Boris Afanasyev, MD DSci, Hervé Dombret, MD, Farhad Ravandi, MD, Hamid Sayar, MD MSc, Jun Ho Jang, MD PhD, Kimmo Porkka, MD, Dominik Selleslag, MD, Irwindeep Sandhu, MD, Mehmet Turgut, MD, Valentina Giai, MD, Yishai Ofran, MD, Merih Kizil Cakar, MD, Aida Botelho de Sousa, MD, Justyna Rybka, MD PhD, Chiara Frairia, MD, Lorenza Borin, MD, Germana Beltrami, MD, Jaroslav Cermak, MD PhD, Gert J. Ossenkoppele, MD PhD, Ignazia La Torre, MD, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, CL Beach, PharmD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_2): LBA-3.
https://doi.org/10.1182/blood-2019-132405
Published: 2019
Journal Articles

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, G. David Roodman, MD PhD, Larry D. Cripe, MD, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Katie J Sargent, RN, Hamid Sayar, MD MSc, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5051.
https://doi.org/10.1182/blood-2019-124384
Published: 2019
Journal Articles

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Larry D Cripe, MD, Katie J Sargent, RN, G. David Roodman, MD PhD, Hamid Sayar, MD MSc, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Rajasubramaniam Shanmugam, PhD, Adriana Rogozea, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3949.
https://doi.org/10.1182/blood-2018-99-111181
Published: 2018
Journal Articles

Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics

Antoine N Saliba, MD, H. Scott Boswell, MD, Larry D Cripe, MD, Mohammad Issam Abu Zaid, MBBS, Jill Weisenbach, RN, OCN, Hamid Sayar, MD MSc
Journal: Blood
Blood (2017) 130 (Supplement 1): 3897.
https://doi.org/10.1182/blood.V130.Suppl_1.3897.3897
Published: 2017
Journal Articles

Pilot Study Of Erlotinib In Patients With Acute Myeloid Leukemia

Hamid Sayar, MD, MSc, Magdalena Czader, MD, PhD, Chirag Amin, MD, Mary Cangany, Bsc, Larry D Cripe, MD
Journal: Blood
Blood (2013) 122 (21): 5037.
https://doi.org/10.1182/blood.V122.21.5037.5037
Published: 2013